Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population.

Barrios V, Escobar C, Calderon A, Ribas L, Marti D, Asin E.

Blood Press. 2008;17(2):110-5. doi: 10.1080/08037050802059092.

PMID:
18568700
2.

Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study.

Calderón A, Barrios V, Escobar C, Ferrer E, Barrios S, González-Pedel V, Montoro P, Navarro-Cid J.

Clin Exp Hypertens. 2010 May;32(3):145-53. doi: 10.3109/10641960903254455.

PMID:
20504121
3.

[Blood pressure control in hypertensive patients with left ventricular hypertrophy. The VIIDA Study].

Bertomeu V, Fácila L, González-Juanatey JR, Cea-Calvo L, Aznar J, Mazón P, Bertomeu González V; VIIDA Study Researchers.

Rev Esp Cardiol. 2007 Dec;60(12):1257-63. Spanish.

4.

Prevalence of left ventricular hypertrophy as assessed by electrocardiogram in treated hypertensive persons in general practice.

van den Hoogen JP, van Kruijsdijk MC, van Ree JW, Mokkink HG, Thien T, van Weel C.

J Hum Hypertens. 1993 Oct;7(5):473-7.

PMID:
8263888
5.

Trends in hypertension control and left ventricular hypertrophy over three years.

Cuspidi C, Michey I, Meani S, Severgnini B, Fusi V, Salerno M, Valerio C, Magrini F, Zanchetti A.

Ital Heart J. 2002 Sep;3(9):514-9.

PMID:
12407847
6.

[Left ventricular hypertrophy in the Spanish hypertensive population. The ERIC-HTA study].

Lozano JV, Redón J, Cea-Calvo L, Fernández-Pérez C, Navarro J, Bonet A, González-Esteban J.

Rev Esp Cardiol. 2006 Feb;59(2):136-42. Spanish.

7.

[Electrocardiographic criteria for left ventricular hypertrophy and cardiovascular risk in hypertensives. VIIDA study].

González-Juanatey JR, Cea-Calvo L, Bertomeu V, Aznar J; for Investigators study VIIDA.

Rev Esp Cardiol. 2007 Feb;60(2):148-56. Spanish.

8.

Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.

Palmieri V, Okin PM, de Simone G, Bella JN, Wachtell K, Gerdts E, Boman K, Nieminen MS, Dahlöf B, Devereux RB.

J Hypertens. 2007 May;25(5):1079-85.

PMID:
17414673
9.

Prevalence of left ventricular hypertrophy in Finnish primary health care hypertensive patients.

Kumpusalo E, Lappi J, Miettinen H, Takala J.

J Hum Hypertens. 2001 Apr;15(4):255-8.

10.

Prevalence and determinants of left ventricular hypertrophy and remodelling patterns in hypertensive patients: the St. Petersburg study.

Conrady AO, Rudomanov OG, Zaharov DV, Krutikov AN, Vahrameeva NV, Yakovleva OI, Alexeeva NP, Shlyakhto EV.

Blood Press. 2004;13(2):101-9.

PMID:
15182113
11.

Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study.

Barrios V, Calderón A, Escobar C, Barrios S, Navarro-Cid J, González-Pedel V, Vegazo O, Fernandez R.

J Hypertens. 2007 Sep;25(9):1967-73.

PMID:
17762663
12.

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators.

Ann Intern Med. 2007 Sep 4;147(5):311-9.

PMID:
17785486
13.

[Left ventricular hypertrophy among hypertensive patients with diminished glomerular filtration rate].

Grabysa R, Cholewa M.

Pol Merkur Lekarski. 2008 Oct;25(148):309-14. Polish.

PMID:
19145927
14.

Electrocardiographic left ventricular hypertrophy and arterial stiffness: the Ohasama study.

Watabe D, Hashimoto J, Hatanaka R, Hanazawa T, Ohba H, Ohkubo T, Kikuya M, Totsune K, Imai Y.

Am J Hypertens. 2006 Dec;19(12):1199-205.

PMID:
17161763
15.

Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.

Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B; LIFE Study Investigators.

Circulation. 2006 Mar 28;113(12):1588-96. Epub 2006 Mar 13.

17.

Left ventricular mass and hypertrophy assessment by means of the QRS complex voltage-independent measurements.

Sosnowski M, Korzeniowska B, Tendera M.

Int J Cardiol. 2006 Jan 26;106(3):382-9. Epub 2005 Jul 5.

PMID:
15996771
18.

Relationship of the electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study. Losartan Intervention For End point.

Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Dahlöf B.

J Am Coll Cardiol. 2001 Aug;38(2):514-20.

19.

The determinants of left ventricular hypertrophy defined by Sokolow-Lyon criteria in untreated hypertensive patients.

Antikainen R, Grodzicki T, Palmer AJ, Beevers DG, Coles EC, Webster J, Bulpitt CJ.

J Hum Hypertens. 2003 Mar;17(3):159-64.

PMID:
12624605
20.

Correlation of electrocardiographic left ventricular hypertrophy criteria with left ventricular mass by echocardiogram in obese hypertensive patients.

da Costa W, Riera AR, Costa Fde A, Bombig MT, de Paola AA, Carvalho AC, Fonseca FH, Luna Filho B, Póvoa R.

J Electrocardiol. 2008 Nov-Dec;41(6):724-9. doi: 10.1016/j.jelectrocard.2008.05.010.

PMID:
18954613

Supplemental Content

Support Center